Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 0.29
(-8.63%)
SEK 0.29
(-8.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -14.68 Million SEK | 73.3% |
| 2022 | -54.97 Million SEK | -9.71% |
| 2021 | -50.1 Million SEK | -2.81% |
| 2020 | -48.73 Million SEK | -131.07% |
| 2019 | -21.09 Million SEK | 22.72% |
| 2018 | -27.29 Million SEK | -122.42% |
| 2017 | -12.27 Million SEK | 15.23% |
| 2016 | -14.47 Million SEK | -158.85% |
| 2015 | -5.59 Million SEK | -828.69% |
| 2014 | -602.14 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.97 Million SEK | 29.67% |
| 2024 Q1 | -2.81 Million SEK | 59.45% |
| 2023 Q2 | -9.53 Million SEK | -118.9% |
| 2023 Q3 | -9.63 Million SEK | -1.09% |
| 2023 FY | -14.89 Million SEK | 72.91% |
| 2023 Q4 | -6.94 Million SEK | 27.97% |
| 2023 Q1 | -4.35 Million SEK | 53.26% |
| 2022 Q2 | -13.39 Million SEK | 30.01% |
| 2022 Q1 | -19.14 Million SEK | 51.18% |
| 2022 Q4 | -9.31 Million SEK | 28.97% |
| 2022 FY | -54.97 Million SEK | -9.71% |
| 2022 Q3 | -13.11 Million SEK | 2.11% |
| 2021 Q3 | -14.51 Million SEK | -4.4% |
| 2021 Q2 | -13.9 Million SEK | -179.34% |
| 2021 Q4 | -39.21 Million SEK | -170.09% |
| 2021 FY | -50.1 Million SEK | -2.81% |
| 2021 Q1 | 17.52 Million SEK | 206.39% |
| 2020 Q3 | -12.65 Million SEK | -35.19% |
| 2020 FY | -48.73 Million SEK | -131.07% |
| 2020 Q4 | -16.47 Million SEK | -30.2% |
| 2020 Q2 | -9.35 Million SEK | 8.73% |
| 2020 Q1 | -10.25 Million SEK | -146.08% |
| 2019 Q3 | -6.99 Million SEK | 10.88% |
| 2019 Q2 | -7.84 Million SEK | -276.76% |
| 2019 Q1 | -2.08 Million SEK | 86.33% |
| 2019 FY | -21.09 Million SEK | 22.72% |
| 2019 Q4 | -4.16 Million SEK | 40.42% |
| 2018 Q1 | -3.84 Million SEK | 7.77% |
| 2018 FY | -27.29 Million SEK | -122.42% |
| 2018 Q3 | -3.72 Million SEK | 17.1% |
| 2018 Q2 | -4.49 Million SEK | -16.86% |
| 2018 Q4 | -15.23 Million SEK | -309.05% |
| 2017 Q2 | -3.46 Million SEK | -9.29% |
| 2017 Q4 | -4.16 Million SEK | -185.48% |
| 2017 Q3 | -1.46 Million SEK | 57.91% |
| 2017 FY | -12.27 Million SEK | 15.23% |
| 2017 Q1 | -3.17 Million SEK | -5.13% |
| 2016 Q3 | -3.16 Million SEK | 28.85% |
| 2016 FY | -14.47 Million SEK | -158.85% |
| 2016 Q4 | -3.01 Million SEK | 4.64% |
| 2016 Q1 | -3.84 Million SEK | -5.0% |
| 2016 Q2 | -4.45 Million SEK | -15.89% |
| 2015 Q1 | -233.5 Thousand SEK | 0.0% |
| 2015 Q2 | -467 Thousand SEK | -100.0% |
| 2015 Q3 | -1.5 Million SEK | -222.91% |
| 2015 Q4 | -3.65 Million SEK | -142.51% |
| 2015 FY | -5.59 Million SEK | -828.69% |
| 2014 FY | -602.14 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -10.801% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 61.633% |
| BioGaia AB (publ) | 440.9 Million SEK | 103.329% |
| Enzymatica AB (publ) | -48.06 Million SEK | 69.456% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 64.912% |
| Gabather AB (publ) | -9.47 Million SEK | -54.95% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 46.546% |
| Nanexa AB (publ) | -76.62 Million SEK | 80.842% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -4.276% |
| ODI Pharma AB | -1.34 Million SEK | -994.183% |
| Orexo AB (publ) | -109.5 Million SEK | 86.594% |
| Probi AB (publ) | 11.32 Million SEK | 229.682% |
| Swedencare AB (publ) | 173.2 Million SEK | 108.476% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.315% |
| Toleranzia AB | -7.89 Million SEK | -86.035% |
| Vivesto AB | -356.71 Million SEK | 95.885% |